Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials
Saba C, Clifford C, Burgess K, Phillips B, Vail D, Wright Z, Curran K, Fan T, Elmslie R, Post G, Thamm D. Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Veterinary And Comparative Oncology 2020, 18: 763-769. PMID: 32346934, PMCID: PMC7754483, DOI: 10.1111/vco.12605.Peer-Reviewed Original ResearchConceptsLarge cell lymphomaCell lymphomaOverall median progression-free intervalMedian progression-free intervalAdverse event evaluationAdverse event profileMinute intravenous infusionProgression-free intervalProspective clinical trialsT-cell immunophenotypeOverall response rateSubstantial antitumour activityDrug-resistant relapseRelapsed subjectsSupportive treatmentUntreated dogsUntreated lymphomaConcurrent corticosteroidsDosage adjustmentPulmonary fibrosisEvent profileGastrointestinal originGroup criteriaIntravenous infusionInferior outcomes